WO2009024834A3 - Acides nucléiques impliques dans les infections virales - Google Patents
Acides nucléiques impliques dans les infections virales Download PDFInfo
- Publication number
- WO2009024834A3 WO2009024834A3 PCT/IB2007/004718 IB2007004718W WO2009024834A3 WO 2009024834 A3 WO2009024834 A3 WO 2009024834A3 IB 2007004718 W IB2007004718 W IB 2007004718W WO 2009024834 A3 WO2009024834 A3 WO 2009024834A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viral infection
- nucleic acids
- acids involved
- hiv
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
L'invention concerne des acides nucléiques humains viraux isolés, associés aux infections virales, ainsi que diverses molécules d'acides nucléiques connexes ou dérivées de ceux-ci. Les acides nucléiques selon l'invention peuvent être utiles dans la prévention, le diagnostic et le traitement des infections virales.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/517,760 US8481506B2 (en) | 2006-12-05 | 2007-12-05 | Nucleic acids involved in viral infection |
US13/986,802 US20140179757A1 (en) | 2006-12-05 | 2013-06-06 | Nucleic acids involved in viral infection |
US14/796,112 US20160002639A1 (en) | 2006-12-05 | 2015-07-10 | Nucleic acids involved in viral infection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86866606P | 2006-12-05 | 2006-12-05 | |
US60/868,666 | 2006-12-05 | ||
US97126507P | 2007-09-11 | 2007-09-11 | |
US60/971,265 | 2007-09-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/517,760 A-371-Of-International US8481506B2 (en) | 2006-12-05 | 2007-12-05 | Nucleic acids involved in viral infection |
US13/986,802 Division US20140179757A1 (en) | 2006-12-05 | 2013-06-06 | Nucleic acids involved in viral infection |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2009024834A2 WO2009024834A2 (fr) | 2009-02-26 |
WO2009024834A8 WO2009024834A8 (fr) | 2009-10-01 |
WO2009024834A3 true WO2009024834A3 (fr) | 2011-12-29 |
Family
ID=40378751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/004718 WO2009024834A2 (fr) | 2006-12-05 | 2007-12-05 | Acides nucléiques impliques dans les infections virales |
Country Status (2)
Country | Link |
---|---|
US (3) | US8481506B2 (fr) |
WO (1) | WO2009024834A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
DE602008005188D1 (de) * | 2007-10-31 | 2011-04-07 | Debiopharm Sa | Beinahe gesamtgenom-test für resistenz gegen hcv-wirkstoff |
WO2009111493A1 (fr) * | 2008-03-03 | 2009-09-11 | Duke University | Microarn viraux |
EP2631240A1 (fr) * | 2009-05-22 | 2013-08-28 | Intelligent Medical Devices, Inc. | Sondes et amorces optimisées et leurs procédés d'utilisation pour la détection, le criblage, la quantification, l'isolement et le séquençage de Cytomégalovirus et de virus Epstein-Barr |
EP2630241B1 (fr) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua |
EP2546358A1 (fr) * | 2011-07-15 | 2013-01-16 | Laboratorios Del. Dr. Esteve, S.A. | Procédés et réactifs pour un contrôle efficace de la progression du VIH |
WO2013067873A1 (fr) * | 2011-11-09 | 2013-05-16 | 南京森楠生物技术研究有限公司 | Acide nucléique, ou acide nucléique peptidique dirigé contre le virus de la grippe et formulation de ceux-ci |
CA2867420A1 (fr) * | 2012-03-19 | 2013-09-26 | Prestizia | Procedes de determination du tropisme et de l'utilisation d'un recepteur d'un virus, en particulier du vih, dans des echantillons corporels preleves a partir de la circulation |
WO2013173774A2 (fr) * | 2012-05-18 | 2013-11-21 | Pathogenica, Inc. | Sondes d'inversion moléculaire |
CN103589721A (zh) * | 2012-08-15 | 2014-02-19 | 北京命码生科科技有限公司 | 植物微小核糖核酸的提取、制备及其应用 |
CN104694541A (zh) * | 2013-12-09 | 2015-06-10 | 江苏命码生物科技有限公司 | 禽流感病毒miRNA及其鉴定、检测和应用 |
CA2949710A1 (fr) * | 2014-05-30 | 2015-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et methodes pour traiter des infections virales latentes |
MA41349A (fr) * | 2015-01-14 | 2017-11-21 | Univ Temple | Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn |
KR101652806B1 (ko) * | 2015-08-21 | 2016-09-01 | 주식회사 엠모니터 | Lamp를 이용한 인플루엔자 검출용 프라이머 및 그 용도 |
WO2017075475A1 (fr) * | 2015-10-30 | 2017-05-04 | Editas Medicine, Inc. | Méthodes et compositions liées à crispr/cas pour le traitement du virus de l'herpès simplex |
EP3525816A4 (fr) * | 2016-10-11 | 2020-08-05 | Yale University | Méthodes de détection d'infection virale respiratoire |
WO2021011493A1 (fr) * | 2019-07-12 | 2021-01-21 | Duke University | Système d'ingénierie 3'utr crispr-dcas 13 et ses procédés d'utilisation |
WO2024026418A1 (fr) * | 2022-07-28 | 2024-02-01 | New York University | Ciblage d'arn chromr non codant long dans une inflammation médiée par l'interféron chez l'homme |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033978A1 (en) * | 1992-09-10 | 2004-02-19 | Anderson Kevin P. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
WO2005116250A2 (fr) * | 2004-05-26 | 2005-12-08 | Rosetta Genomics Ltd. | Arnmi viraux ou associes aux virus et leur utilisation |
US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
WO2006110762A2 (fr) * | 2005-04-11 | 2006-10-19 | Achillion | Compositions pharmaceutiques et methodes d'inhibition de la replication du vhc |
US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
WO1993023569A1 (fr) | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif d'inhibition de la replication virale |
WO1994002595A1 (fr) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif pour le traitement de maladies chez les animaux |
US5342790A (en) * | 1992-10-30 | 1994-08-30 | Becton Dickinson And Company | Apparatus for indirect fluorescent assay of blood samples |
US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
US5580731A (en) * | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5591554A (en) | 1996-01-11 | 1997-01-07 | Xerox Corporation | Multilayered photoreceptor with adhesive and intermediate layers |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
CN1361829A (zh) | 1999-03-18 | 2002-07-31 | 埃克西库恩公司 | 利用特异性lna引物检测基因突变 |
EP1620544B1 (fr) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | Agents modifies d'arni |
CA2533701A1 (fr) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants |
US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
-
2007
- 2007-12-05 WO PCT/IB2007/004718 patent/WO2009024834A2/fr active Application Filing
- 2007-12-05 US US12/517,760 patent/US8481506B2/en active Active
-
2013
- 2013-06-06 US US13/986,802 patent/US20140179757A1/en not_active Abandoned
-
2015
- 2015-07-10 US US14/796,112 patent/US20160002639A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033978A1 (en) * | 1992-09-10 | 2004-02-19 | Anderson Kevin P. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
WO2005116250A2 (fr) * | 2004-05-26 | 2005-12-08 | Rosetta Genomics Ltd. | Arnmi viraux ou associes aux virus et leur utilisation |
US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
WO2006110762A2 (fr) * | 2005-04-11 | 2006-10-19 | Achillion | Compositions pharmaceutiques et methodes d'inhibition de la replication du vhc |
Non-Patent Citations (2)
Title |
---|
DATABASE GENBANK 23 January 2009 (2009-01-23), "Sequence 2015 from Patent W02005116250", Database accession no. FB989997 * |
DATABASE GENBANK 29 June 2009 (2009-06-29), "Sequence 1209 from Patent W02005116250", Database accession no. F8989191 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009024834A2 (fr) | 2009-02-26 |
WO2009024834A8 (fr) | 2009-10-01 |
US8481506B2 (en) | 2013-07-09 |
US20140179757A1 (en) | 2014-06-26 |
US20160002639A1 (en) | 2016-01-07 |
US20100184205A1 (en) | 2010-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009024834A3 (fr) | Acides nucléiques impliques dans les infections virales | |
USD652306S1 (en) | Bottle | |
USD602171S1 (en) | Concrete block | |
WO2006069064A3 (fr) | Sequences vhb et vhc conservees utilisees pour un silençage genique | |
WO2008014521A8 (fr) | Vaccins améliorés et leurs procédés d'utilisation | |
HK1123055A1 (en) | Hepatitis c virus nucleic acid vaccine | |
WO2009094190A3 (fr) | Méthodes de traitement d’infections virales | |
NZ598000A (en) | Composition for treating hbv infection | |
CL2007002284A1 (es) | Compuestos derivados de tetrazolilos macrociclicos; proceso de preparacion; composicion farmaceutica; y uso para tratar una infeccion viral de hepatitis c. | |
WO2008113011A3 (fr) | Purification de particules de type virus | |
WO2010021681A3 (fr) | Compositions et procédés pour le traitement de maladies virales | |
IL203869A (en) | Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method | |
WO2008076371A3 (fr) | Procédé destiné à répliquer le virus de la grippe en culture | |
HK1124084A1 (en) | Nucleic acid for treatment or prevention of immunodeficiency virus infection | |
WO2009080806A3 (fr) | Virus influenza modifié | |
WO2012016139A3 (fr) | Compositions d'arnsi et procédés de traitement d'infections par le hpv et d'autres infections | |
ZA200706306B (en) | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase | |
EP2120988A4 (fr) | Traitement de l'infection par le virus de l'hépatite c | |
WO2010041241A3 (fr) | Peptides dérivés de l'intégrase du vih-1 et compositions | |
WO2009029681A3 (fr) | Micro-arn utilisés pour inhiber la réplication virale | |
WO2007038316A3 (fr) | Genes promoteurs de latence du cytomegalovirus humain, variantes de virus apparentees et leurs methodes d'utilisation | |
WO2007144569A3 (fr) | Produit antiviral | |
WO2008118879A3 (fr) | Composés et compositions antivirales | |
MY149148A (en) | Protein-polymer conjugates | |
HRP20140230T8 (hr) | Biljna kompozicija za lijeäśenje ili prevenciju virusnih bolesti koje se prenose putem krvi, kao što su bolesti izazvane virusom humane imunodeficijencije (hiv) ili hepatitis c virusom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07875186 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07875186 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12517760 Country of ref document: US |